n.a. (ELN)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Div & Yield N.A. (N.A)
Elan Announces Restructuring Of Tysabri Collaboration With Biogen Idec

Elan Announces Restructuring Of Tysabri Collaboration With Biogen Idec

Elan Corporation, plc (NYSE:ELN) today announced that it has agreed to restructure the Tysabri® collaboration with Biogen Idec.

Elan Reports Fourth Quarter And Full-Year 2012 Financial Results

Elan Reports Fourth Quarter And Full-Year 2012 Financial Results

Elan Corporation, plc today reported its fourth quarter and full-year 2012 financial results.

Elan Sells Its Remaining Stake In Alkermes

Elan Sells Its Remaining Stake In Alkermes

Elan Corporation, plc (“Elan”) (NYSE: ELN) announced that, following the close of trading today, Elan, through its wholly-owned subsidiary, Elan Science Three Limited, agreed to sell, on customary terms, all of...

Elan Announces Webcast Of Fourth Quarter And Full-Year 2012 Financial Results

Elan Announces Webcast Of Fourth Quarter And Full-Year 2012 Financial Results

Elan Corporation, plc (NYSE: ELN) announced today that it will host a conference call on Wednesday, February 6, 2013 at 8:30 a.

Lieff Cabraser Reminds Elan Corporation, Plc Investors Of Upcoming Deadline In Class Action Lawsuits

Lieff Cabraser Reminds Elan Corporation, Plc Investors Of Upcoming Deadline In Class Action Lawsuits

Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the February 5, 2013 deadline to move for appointment as lead plaintiff in the securities class litigation brought on behalf of persons who...

Brower Piven Encourages Investors Who Purchased Tens Of Thousands Of Elan Corporation, Plc American Depositary Receipts Or More To Inquire About The Lead Plaintiff Position In Securities Fraud Class Action Lawsuit

Brower Piven Encourages Investors Who Purchased Tens Of Thousands Of Elan Corporation, Plc American Depositary Receipts Or More To Inquire About The Lead Plaintiff Position In Securities Fraud Class Action Lawsuit

Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of all persons who purchased or ...

Biogen Idec And Elan Submit Applications For First-Line Use Of TYSABRI In Anti-JCV Antibody Negative Patients With MS

Biogen Idec And Elan Submit Applications For First-Line Use Of TYSABRI In Anti-JCV Antibody Negative Patients With MS

Today Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced that they have submitted applications to the U.

Lieff, Cabraser, Heimann & Bernstein, LLP Announces Class Action Lawsuits On Behalf Of Elan Corporation, Plc Investors Against S.A.C. Capital Advisors, LP And Its Affiliates

Lieff, Cabraser, Heimann & Bernstein, LLP Announces Class Action Lawsuits On Behalf Of Elan Corporation, Plc Investors Against S.A.C. Capital Advisors, LP And Its Affiliates

The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action lawsuits have been brought on behalf of all persons who purchased or otherwise acquired the American Depositary Shares...

The Law Firm Of Wohl & Fruchter LLP Files Class Action On Behalf Of Investors In Elan Corporation, Plc Arising From Insider Trading By S.A.C. Capital Advisors, L.P. And Affiliates

The Law Firm Of Wohl & Fruchter LLP Files Class Action On Behalf Of Investors In Elan Corporation, Plc Arising From Insider Trading By S.A.C. Capital Advisors, L.P. And Affiliates

The law firm of Wohl & Fruchter LLP announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York on behalf of investors who purchased American ...

Elan Announces Completion Of Demerger Of Prothena Corporation Plc

Elan Announces Completion Of Demerger Of Prothena Corporation Plc

Elan Corporation, plc (NYSE:ELN) today announced completion of the separation of a substantial portion of its drug discovery business (the Prothena Business) into a new independent, publicly traded company, Prothena...

Elan Announces Availability Of Information Statement In Respect Of Prothena Corporation Plc

Elan Announces Availability Of Information Statement In Respect Of Prothena Corporation Plc

Elan Corporation, plc (NYSE: ELN) announces that the information statement in respect of Prothena Corporation plc, which is being provided to holders of record of Elan ordinary shares and ADSs as of December 14, 2012...

Elan Announces Expected Timetable In Respect Of Implementation Of Proposed Demerger

Elan Announces Expected Timetable In Respect Of Implementation Of Proposed Demerger

Elan Corporation, plc (NYSE: ELN) today announced the expected timetable of the separation of a substantial portion of its drug discovery business (the Prothena Business) into a new independent, publicly traded ...

Resolution To Approve The Prothena Business Demerger Passed At Elan EGM

Resolution To Approve The Prothena Business Demerger Passed At Elan EGM

Elan Corporation, plc (NYSE: ELN) announces that, at an Extraordinary General Meeting (EGM) held earlier today, the sole ordinary resolution to approve the demerger of the Prothena Business was duly passed.

Elan Announces Record Date In Respect Of Proposed Demerger

Elan Announces Record Date In Respect Of Proposed Demerger

Elan Corporation, plc (NYSE: ELN) announced today that it has established 11.

The Digital Skeptic: Insider Trading? Why Even Bother?

The Digital Skeptic: Insider Trading? Why Even Bother?

We live in an information age, and the insider information investors is seek is probably available -- with no legal risk.

Elan Announces Enrollment Of First Patient In Phase 2 Study Of ELND005 (Scyllo-inositol) For The Treatment Of Agitation/Aggression In Patients With Alzheimer’s Disease

Elan Announces Enrollment Of First Patient In Phase 2 Study Of ELND005 (Scyllo-inositol) For The Treatment Of Agitation/Aggression In Patients With Alzheimer’s Disease

Elan Corporation, plc (NYSE: ELN) today announced that it has enrolled the first patient in a Phase 2 clinical trial of ELND005 (Study AG201) for the treatment of agitation/aggression in patients with moderate to ...

SAC's Alleged Insider Trade Hid in Dark Pools

SAC's Alleged Insider Trade Hid in Dark Pools

The U.S. attorney's charge against a SAC trader highlights the opacity of so-called 'dark pools.'

Elan Announces Publication Of EGM Circular In Respect Of Proposed Demerger

Elan Announces Publication Of EGM Circular In Respect Of Proposed Demerger

Elan Corporation, plc (NYSE: ELN) today announced the publication and filing of a circular to shareholders convening an extraordinary general meeting (“EGM”) to be held in the Davenport Hotel, 8/10 Merrion Street...

Elan Reports Third Quarter 2012 Financial Results

Elan Reports Third Quarter 2012 Financial Results

Elan Corporation, plc today reported its third quarter and first nine months 2012 financial results.

Elan Announces Expiration Of Cash Tender Offer And Consent Solicitation For 8.75% Senior Notes Due 2016

Elan Announces Expiration Of Cash Tender Offer And Consent Solicitation For 8.75% Senior Notes Due 2016

Elan Corporation, plc (“Elan”) (NYSE: ELN) announced today the expiration and final results of the cash tender offer and consent solicitation (the “Tender Offer and Consent Solicitation”), commenced on...

TYSABRI® (natalizumab) Data At ECTRIMS Reaffirm Positive Effects Of Treatment For People With Relapsing Forms Of MS

TYSABRI® (natalizumab) Data At ECTRIMS Reaffirm Positive Effects Of Treatment For People With Relapsing Forms Of MS

Today, Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced that results from 11 company-sponsored TYSABRI presentations, including 10 posters and one platform, will be available for...

Elan Announces Webcast Of Third Quarter 2012 Financial Results

Elan Announces Webcast Of Third Quarter 2012 Financial Results

Elan Corporation, plc (NYSE: ELN) announced today that it will host a conference call on Wednesday, October 24, 2012 at 8:30 a.

Elan Announces Results Through Consent Payment Deadline Of Cash Tender Offer And Consent Solicitation For 8.75% Senior Notes Due 2016

Elan Announces Results Through Consent Payment Deadline Of Cash Tender Offer And Consent Solicitation For 8.75% Senior Notes Due 2016

Elan Corporation, plc (“Elan”) (NYSE: ELN) announced today the results, as of 11:59 p.

Elan Announces Redemption Of Its Senior Notes Due 2016

Elan Announces Redemption Of Its Senior Notes Due 2016

Elan Corporation, plc (“Elan”) (NYSE: ELN) announced today that it will redeem all of the Senior Notes due 2016 issued on October 2, 2009 (the “2009 Notes”) and Senior Notes due 2016 issued on August...

Elan Announces Pricing Of $600 Million 2019 Senior Notes

Elan Announces Pricing Of $600 Million 2019 Senior Notes

Elan Corporation, plc (“Elan”) (NYSE: ELN) today announced the pricing of the offering of US$600 million aggregate principal amount of 6.

Elan Announces Intent To Offer US$500 Million In Aggregate Principal Amount Of Senior Notes Due 2019

Elan Announces Intent To Offer US$500 Million In Aggregate Principal Amount Of Senior Notes Due 2019

Elan Corporation, plc (“Elan”) (NYSE: ELN) today announced that its wholly-owned subsidiaries, Elan Finance public limited company (“Elan Finance”) and Elan Finance Corp.

Elan Announces Commencement Of Tender Offer And Consent Solicitation

Elan Announces Commencement Of Tender Offer And Consent Solicitation

Elan Corporation, plc (“Elan”) (NYSE: ELN) today announced that its wholly-owned subsidiaries, Elan Finance public limited company (“Elan Finance”) and Elan Finance Corp.

Elan Announces The Appointment Of Hans Peter Hasler As Chief Operating Officer

Elan Announces The Appointment Of Hans Peter Hasler As Chief Operating Officer

Elan Corporation, plc (NYSE:ELN) today announced the appointment of Hans Peter Hasler as Chief Operating Officer (“COO”) of the Company with effect from October 1, 2012.

The Targacept Secret That Wall Street Doesn't Want You to Know About

The Targacept Secret That Wall Street Doesn't Want You to Know About

There's a reason why Fidelity and others big investors continue to stick with Targacept despite clinical trail failures.

Elan Announces Dosing Of First Patient In Phase 2 Trial Of ELND005 (Scyllo-inositol) In Bipolar Disorder

Elan Announces Dosing Of First Patient In Phase 2 Trial Of ELND005 (Scyllo-inositol) In Bipolar Disorder

Elan Corporation, plc (NYSE:ELN) today announced that it has commenced a Phase 2, placebo-controlled, safety and efficacy study of oral ELND005 as an adjunctive maintenance treatment in patients with Bipolar I Disorder...